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Introduction
The impact of glycaemic control on in-patient mortality has been 
long debated and the optimal target range for blood glucose in 
critically ill patients remains unclear. Hyperglycaemia, defined 
by a blood-glucose level exceeding the normal fasting level of 
5.5 mmol/l is common during critical illness.1 Glucose elevation 
in critically ill patients is commonly attributed to associated 
increased levels of cortisol, glucagon and adrenaline, thus 
resulting in increased gluconeogenesis and decreased peripheral 
uptake of glucose, hence leading to high circulating levels of 
glucose.2 This glucose elevation increases the cellular glucose 
overload and associated pronounced side effects of glycolysis 
and oxidative phosphorylation, thereby causing irreversible 
damage to cellular function and structure, reflected by various 
organ dysfunctions (liver, renal, cardiac, endothelial and cellular 
immune system).3,4 Although this stress hyperglycaemia was 
long deemed to be a beneficial, adaptive response to provide 
energy to those organs that predominantly rely on glucose as 
metabolic substrate, many studies have confirmed that there is 
a link between hyperglycaemia and increased mortality.5 In fact, 
Mesotten D and Van den Berghe G,5 showed that the statistical 
association between blood-glucose level and risk of death, 
in many observational studies follows a J-shaped curve, with 
normal, fasting blood levels associated with lowest risk of death. 
Intensive versus conventional glucose control
The choice of blood sugar control technique (conventional versus 
intensive control) in the ICU, however, has long been debated. 
Insulin-based treatment regimens decrease morbidity and 
mortality in critically ill patients,6 yet tight control of blood sugar, 
was not favoured by many intensivists – due to an increased 
risk of hypoglycaemia.  Hypoglycaemia remains the most 
significant concern regarding implementation of tight glucose 
control policies because it can induce irreversible brain lesions. 
Severe hypoglycaemia (<2.2 mmol/l)7 has been shown to be an 
independent risk factor for mortality in the ICU8 and it occurs 
5-10 times more in intensive glucose control (IGC) as compared 
to conventional glucose control (CGC). Moreover, as the majority 
of ICU patients have decreased levels of consciousness and 
increased stress, the detection of hypoglycaemia in these 
patients depends solely on glucose monitoring. 
From an economic standpoint, a cost analysis study of IGC in 
critically ill adult patients revealed that IGC saved an average 
of $1580 per patient9 attributed to shorter ICU and hospital 
length of stay, decreased ventilator-dependent days, and 
reduced total laboratory costs. In another study on mechanically 
ventilated patients admitted to a surgical ICU, the excess cost of 
hospitalisation in patients treated with CGC compared to those 
treated according to the IGC regimen was €2638 per patient.10 
Hence, given the improved clinical outcomes of IGC and its cost 
effectiveness, it is probably worth pursuing.
To show a relationship between hyperglycaemia and mortality 
risk, many randomised controlled trials (RCTs) that target and 
achieve different blood-glucose levels have been conducted. The 
2001 Leuven Surgical Trial11 was one of the first to demonstrate 
a clinical benefit amongst predominantly surgical ICU patients 
treated with IGC. Subsequent RCTs were then conducted in 
a heterogeneous population in ICU, but these studies failed 
to support the subsequent benefit of these intensive glucose 
control practices in this environment, probably because these 
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investigations lack the methodological rigor of the initial studies 
and have provided few data that can be effectively extrapolated 
to the care of the ICU population.12 Table 1 shows the different 
studies conducted “for and against” a tight glucose control policy.
The NICE-SUGAR encountered major criticisms:12 
•	 The use of different target ranges for blood glucose in 
the control and interventional groups (7.7-10 mmol/l vs 
10-11.9 mmol/l in Leuven studies
•	 Different routes for insulin administration; types of infusion 
system used
•	 Difference in sampling sites
•	 Different glucometers used and difference in nutritional 
strategies.
Despite these criticisms, this trial contradicted and over-rode the 
trend towards IGC in the ICU that began with the earlier Leuven 
trials. Therefore, in view of the detrimental effects shown by NICE-
SUGAR trial, IGC cannot be generally recommended for all ICUs. 
Although the ideal target glucose remains unclear, the standard 
of care in many medical and surgical ICUs targets 7.7-10 mmol/l. 
In fact, several guideline-issuing bodies recommend CGC:
•	 The 2012 Surviving Sepsis Campaign recommends a glycaemic 
target of ≤ 10 mmol/l in patients with severe sepsis.19 
•	 The “International recommendations for glucose control in 
adult non-diabetic critically ill patients” strongly suggest 
avoidance of severe hyperglycaemia (> 10 mmol/l) in adult 
ICU patients and avoidance of IGC in an emergency situation.6
•	 The 2009 American Association of Clinical Endocrinologists 
and American  Diabetes Association guidelines recommend a 
goal range of 7.7-10 mmol/l.20 
•	 The 2011 Institute for Healthcare Improvement guidelines 
recommend glucose <10 mmol/l for critically ill patients.21
Blood glucose measurement
To measure point-of-care blood glucose, two common 
procedures are used: venous or arterial blood by way of an intra-
vascular catheter and capillary blood/ finger prick. Venous or 
arterial blood sampling is not only time-consuming but it also 
carries a risk of infection and involves a relatively large amount of 
blood drawn. Finger pricking, however, is prone to measurement 
errors, as shown in a study by Ting C and Nanji AA.22 In their 
study, they found that as many as 62% of values obtained in ICUs 
deviate from the reference laboratory values by >20%. Another 
study23 showed that in shock patients, only 36% of patients 
had finger stick-derived capillary glucose levels within 20% of 
the measured reference. These discrepancies in glucose levels 
Table 1: Summary of intensive/ tight glucose control studies.
Study Study synopsis Results Outcome
Leuven Surgical 
Trial11
In a surgical ICU, IGC (targeting a blood glucose of 
4.4-6.1 mmol/l) was compared to CGC (targeting 
a blood glucose of 10-11.1 mmol/l), particularly 
amongst patients who were in the ICU for ≥ 5 days.
Decrease in ICU morbidity and lower incidence 
of systemic infections, acute renal insufficiency, 
anaemia, polyneuropathy, duration of artificial 




Griesdale et al13 A meta-analysis of 26 RCTs involving a total of 
13 567 patients, intensive insulin therapy was 
compared to conventional insulin therapy in the 
ICU.
Even though intensive insulin therapy significantly 
increased the risk of hypoglycaemia and conferred 
no overall mortality benefit among critically ill 
patients. This this therapy, however, may be 
beneficial to patients admitted to a surgical ICU.
Tight glucose 
control may be 
beneficial to 
patients admitted 
to a surgical ICU.
Wiener et al14 A meta-analysis of 34 RCTs totalling 8 432 patients, 
intensive insulin therapy was compared to 
conventional insulin therapy in the ICU.
Hospital mortality did not differ between IGC 
versus CGC. Even though IGC was associated with 
an increased risk of hypoglycaemia, it was also 
associated with a decreased risk of septicaemia.
Tight glucose 
control may be 
considered to 
decrease risk of 
septicaemia. 
Scalea et al15 Examined the impact of IGC policy on outcomes 
(from a 24 month period before the implementation 
of IGC protocol to a 24 month post intervention 
phase) associated with hyperglycaemia in critically 
injured patients.
IGC group falls in the improving pattern of glucose 
control; and a decrease from 29% to 21% in the 
incidence of early infection (develop in first 2 weeks) 
was observed after introduction of their tight 
glucose control protocol.
Tight glucose 




NICE-SUGAR randomised 6 104 medical and surgical 
ICU patients to IGC (targeting a blood glucose of 
4.5-6 mmol/l) versus CGC (targeting a blood glucose 
of ≤10 mmol/l). 
Increased mortality among medical and surgical ICU 






Designed to assess the efficacy of fluid resuscitation 
and of blood-glucose control (IGC versus usual care) 
in patients with severe sepsis and septic shock. 
In this study, blood glucose targets were 4.4-6.1 
mmol/l and 10–11.1 mmol/l for the intensive and 
control groups respectively. 
The study had to be stopped early after the 
incidence of hypoglycaemia (12.1%) in the IGC 





multicentre trial18  
(larger than the 
VISEP trial)17 
Investigated whether IGC to 4.4-6.1 mmol/l versus 
a conventional target of 7.7–10 mmol/l improves 
survival in critically ill patients. 
The study had to be stopped early because the 
target glycaemic control was not reached and the 




IGC: Intensive Glucose Control, CGC: Conventional Glucose Control, NICE-SUGAR: Normo-glycaemia in Intensive Care Evaluation and Surviving Using Glucose Algorithm 
Regulation, VISEP: Volume substitution and Insulin therapy in severe SEPsis.
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would potentially impact on the dosing of insulin. These may be 
due to device performance, alterations in skin temperature, or 
variations in local perfusion of the site of measurement (usually 
low perfusion states commonly encountered in ICU patients), 
together with increased regional glucose utilization which may 
result in a biased capillary glucose measurement)24,25
Continuous glucose monitoring (CGM) devices
In order to improve ICU outcome, IGC should ideally not be 
associated with hypoglycaemia, increased hospital cost or 
frequent blood sampling, or finger pricking. This may be possible 
with the use of next generation glucose monitoring devices in 
the implementation of tight glucose control strategies. These 
novel devices which provide continuous or near continuous 
monitoring capabilities, give “real-time” glucose readings, thus 
allowing immediate therapeutic adjustments. Glucose levels 
are continuously reported from a small electrode inserted 
into interstitial fluid under the skin, usually in the abdomen or 
upper arm. Almost all the subcutaneous CGM devices on the 
market utilise comparable glucose-oxidase methodology of 
glucose measurement and derive their results from interstitial 
fluid glucose, converted by a specific algorithm to reflect blood 
glucose.24 CGM equipment is typically worn by the patient 
for 3 to 5 days, and is especially useful for detecting nocturnal 
hypoglycaemia or dawn phenomenon and postprandial 
hyperglycaemia, which can be missed by other methods of 
blood glucose monitoring, and hence may have an advantage 
over “point-of-care” testing. 
Designed to successfully improve glucose control, CGM provides 
information about glucose concentration, directional trends 
and rate of change of blood glucose over a period of several 
days. These systems have a sensor life which varies between 
3-7 days and they also have user-set alarms for rate of change 
and predictive alarms for low or high blood glucose levels. 
Having this information, hypo- or hyperglycaemic excursions 
can be avoided and glycaemic control could be improved. 
Thus, mortality and morbidity may possibly be reduced by the 
prevention of newly acquired kidney injury, faster weaning from 
mechanical ventilation and accelerated discharge from the ICU. 
Accuracy of continuous glucose monitoring devices  
in the ICU
Although it seems to be a cost effective technology, the major 
disadvantage of CGM, however, is that the accuracy is not 
equivalent to that of glucose meters, as there is a physiologic lag 
between blood and interstitial space glucose of approximately 
5 to 10 minutes and this lag is accentuated when glucose levels 
are undergoing rapid change.26 Even though some studies27,28 
have demonstrated a reasonable correlation between abdominal 
interstitial fluid and arterial blood glucose measurements in 
critically ill patients in the ICU,  glucose levels in the abdominal 
subcutaneous interstitial fluid may be affected by local blood 
flow and temperature (which may be substantially affected by 
manifestations of critical illness, such as shock, sepsis, or external 
cooling), the dynamics of systemic blood glucose changes, 
and the distance between the sensor and the blood vessel 
supplying the area of interest29 thus creating a major bias in 
glucose assessments. In fact, the relationship of interstitial fluid 
to blood in the critically ill patient , has been investigated only 
to a limited degree. Most of these studies30-37 have evaluated the 
accuracy of CGMs and address specific critical concerns such as 
hypotension, use of inotropes, hypothermia, oedema, renal and 
hepatic failure, hyperinsulinaemia, and acidosis. However, these 
studies were small and generally not powered to assess each of 
those variables. 
Table 2 shows the different studies evaluating the accuracy of 
CGMs and their conclusions. Most studies showed that the 
accuracy of CGMs is not affected by the presence of oedema, 
hypotension, hypothermia, ketosis or inotropic support.30-32,34-36 
However, hyperinsulinaemia itself reduced sensor glucose 
compared with venous glucose readings by about 20% in 
humans.37
In a study by Holzinger et al,38  real-time interstitial fluids CGM 
was compared with point-of-care blood glucose measurements 
to guide intravenous insulin infusion over 72 hours in 124 
Table 2: Effects of different conditions and treatments on the accuracy of CGM devices in the ICU.
Author(s) Year Condition of the patient n Outcomes
Lorencio et al30 2012 Patients on insulin therapy. 41 Accuracy was significantly better in patients with septic shock in comparison 
with the other patient cohorts.
Holzinger et al31 2009 Patients on inotropic support. 50 No interference in accuracy of CGM devices with inotropic therapy.
Price et al32 2008 Patients on inotropic support. 17 No interference in accuracy of CGM devices with inotropic support.
De Block et al33 2006 Septic shock, renal failure and 
patients on inotropic support.
50 Compared with patients on no inotropes and in those without renal failure and 
septic shock, the accuracy is worse in patients on inotropic support and better in 
renal failure and septic shock.
Pfützner et al34 2006 Patients with ketosis. 12 No interference in accuracy of CGM devices in ketosis patients when compared 
with patients without ketosis.
Piper et al35 2006 Patients with ooedema, 
hypothermia, and on inotropes. 
20 No interference in accuracy of CGM devices in such patients when compared 
with the other patient cohorts.
Goldberg et al36 2004 Oedema, hypotension and 
patients on inotropic support.
21 No interference in accuracy of CGM in such patients when compared with 
patients without oedema, hypotension and inotropic support.
Monsod et al37 2002 Hyperinsulinaemia 11 Interference in accuracy of CGM devices with hyperinsulinaemia.
CGM: Continuous glucose monitoring.
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patients on mechanical ventilation. They found that real-time 
CGM reduces hypoglycaemic events but does not improve 
glycaemic control compared with intensive insulin therapy 
guided by an algorithm. A randomised study by Mraz et al,39 
showed that CGM provided better glycaemic control without 
hypoglycaemia in comparison with standard monitoring to 
manage glycaemia in an intensive insulin treatment protocol. In 
another study, Tonyushkina et al40 showed that 97% of readings 
in CGM patients were clinically acceptable with no episodes 
of hypoglycaemia over 24 hours, whereas hypoglycaemia 
occurred in 50% of patients in the control group. However, 
Rabiee et al41 found that the CGM generally overestimated 
the actual serum glucose and missed 50% of the 30 actual 
hypoglycaemic episodes as determined by their glucometer, 
leading the authors to conclude that it was not sufficiently safe 
to be used in an ICU setting. Based on the limited available data 
related to accuracy of CGM devices, the Endocrine Society (USA) 
clinical practice guideline on CGM42 does not recommend the 
use of CGM in ICU settings where patients are unable to provide 
feedback about hypoglycaemic symptoms. They concluded that 
the potential danger in their use in guiding insulin administration 
in an acute care setting outweighs the possible convenience and 
trend awareness that the technology provides. 
The future of continuous glucose monitoring devices: 
intravascular sensors
Automated blood glucose measurement systems that reside in 
the peripheral vein are under development and may be more 
accurate than the current FDA-approved CGM systems that 
monitor glucose via interstitial fluid.43  This will probably minimise 
the sources of bias of capillary and interstitial fluid glucose 
typically encountered in critically ill patients; not to mention that 
it will also minimise risk of contamination and infection involved 
in repetitive sampling from indwelling vascular catheters and 
also reduce medical personnel workload. In their porcine model, 
Skjaervold et al44 reported preliminary data on a novel indwelling 
vascular continuous glucose sensor (which detects blood sugar 
fluctuations over a wide range. From less than 1 mmol/l to more 
than 15 mmol/l), by employing a unique hydrogel matrix that 
changes size continuously in relationship to ambient glucose 
concentrations, thus providing ongoing real-time reporting of 
results.44 This technology, research and concept have paved a 
way towards safer avenues to glucose control in our ICUs.  Until 
the clinical benefit and safety of such state-of-the-art glucose 
management systems is clearly demonstrated in human studies, 
CGM will, however, not be ready for use in glucose control 
protocols in the ICU.
Conclusion
The technology of CGM devices provides a valuable and rapidly 
progressing area of research to determine whether or not the 
application of such novel devices will be sufficient for use with 
intensive insulin therapy in the ICU population. Even though the 
use of CGM appears promising, it must undergo a larger testing 
in the ICU setting before it can be used for implementation of 
tight glucose control policies in the ICU. Further development 
of long-term implantable sensors for measuring glucose 
continuously or as a “real-time” glucose vascular sensor, CGM 
technology could ultimately prove to be a blessing in the ICU, by 
decreasing medical personnel workload and by providing alarm 
signals for impending glycaemic excursions. RCTs examining the 
use of these new technologies to achieve tight glycaemic control 
while minimising the risk of hypoglycaemia would, however, still 
be necessary prior to adopting these devices in critical care.
Sources of financial support
None
Conflicts of interest
The authors certify that there are no actual or potential conflicts 
of interest linked to continuous glucose monitoring devices in 
relation to this article.
References
1. Mizock BA. Alterations in carbohydrate metabolism during stress: a 
review of the literature. The Am J Med 1995; 98: 75–84.
2. Capes SE. Stress hyperglycaemia and increased risk of death 
after myocardial infarction in patients with or without diabetes: a 
systemic overview. Lancet 2000; 355(9206):773-8.
3. Van den Berghe G. How does blood glucose control with insulin 
saves lives in intensive care. J Clin Invest 2006; 114(9):1187-95.
4. Ellger B, Debaveye Y, Vanharebeek I et al. Survival benefits of 
intensive insulin therapy in critical illness: impact of maintaining 
normoglycemia versus glycemia-independent actions of insulin. 
Diabetes 2006; 55(4):1096-105.
5. Mesotten D, Van den Berghe G. Clinical benefits of tight glycaemic 
control: focus on the Intensive Care Unit. Best Pract Res Clin 
Anesthesiol 2009; 23: 421-29.
6. Langley J, Adams G. Insulin-based regimens decrease mortality rates 
in critically ill patients: a systematic review. Diabetes Metab Res Rev. 
2006 Nov 6;23(3):184-92.
7. Ichai C, Preiser JC. International recommendations for glucose 
control in adult non diabetic critically ill patients. Crit Care 2010, 4: 
R166.
8. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin 
therapy in the medical ICU. N Engl J Med 2006; 354: 449-61.
9. Krinsley JS, Jones RL. Cost analysis of intensive glycaemic control in 
critically ill adult patients. Chest. 2006 Mar;129(3):644-50.
10. Van den Berghe G, Wouters PJ, Kesteloot K, et al. Analysis of 
healthcare resource utilization with intensive insulin therapy in 
critically ill patients. Crit Care Med. 2006 Mar;34(3):612-16.
11. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin 
therapy in the critically ill patients. N Engl J Med 2001, 345:1359-67.
12. Du Bose JJ, Scalea TM. Glucose elevation and outcome in critically 
injured trauma patients. Adv Surg 2011; 45:185-96.  
13. Griesdale DEG, de Souza RJ, Van Dam RM, et al. Intensive insulin 
therapy and mortality among critically ill patients: a meta-analysis 
including NICE-SUGAR study data. CMAJ 2009; 180(8):821-27.
14. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight 
glucose control in critically ill adults. A meta-analysis. JAMA 2008; 
300:933-44.
15. Scalea TM, Bochicchio GV, Bochicchio KM. Tight glycemic control in 
critically injured trauma patients. Ann Surg 2007; 246:605-10.
16. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, et al. 
Intensive versus conventional glucose control in critically ill patients. 
N Engl J Med 2009; 360:1283-97.
17. Brunkhorst FM, Engel C, Bloos F, et al. Intensive Insulin Therapy 
and Pentastarch Resuscitation in Severe Sepsis? N Engl J Med 2008; 
358:125-39.
18. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised 
multi-centre controlled trial on tight glucose control by intensive 
insulin therapy in adult intensive care units: the Glucontrol study. 
Intensive Care Med 2009; 35:1738-48.
19. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: 
international guidelines for management of severe sepsis and septic 
shock: 2012. Crit Care Med 2013; 41(2): 580-637. 
Southern African Journal of Anaesthesia and Analgesia 2014; 20(4):185-189
13-14 September 2014, The Forum, BryanstonThe Anaesthetic Foundation Edition 36
189
20. Moghissi ES, Korytkowski MJ, Di Nardo M, et al. American 
Association of Clinical Endocrinologists and American Diabetes 
Association consensus statement on inpatient glycemic control. 
Endocr Pract. 2009; 15(4):353-69. 
21. Institute for Healthcare Improvement Guidelines Implement 
Effective Glucose Control. Available from http/www.ihi.org/
knowledge/pages/changes/implement eac.aspx 
22. Ting C, Nanji AA. Evaluation of the quality of bedside monitoring 
of the blood glucose level in a teaching hospital. CMAJ. 1988 Jan 
1;138(1):23-26.
23. Atkin SH, Dasmahapatra A, Jaker MA, et al. Finger stick 
glucose determination in shock. Ann Intern Med. 1991 Jun 
15;114(12):1020-24.
24. Weiss R, Lazar I. The Need for Continuous Blood Glucose Monitoring 
in the Intensive Care Unit. J Diabetes Sci Technol 2007;1(3):412-14.
25. Haupt A, Berg B, Paschen P, et al. The effects of skin temperature 
and testing site on blood glucose measurements taken by a modern 
blood glucose monitoring device. Diabetes Technol Ther. 2005 
Aug;7(4):597-601.
26. Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two 
continuous glucose monitoring systems. Diabetes Res Clin Pract 
2010; 87:348-53.
27. De Block C, Vertommen J, Manuel-y-Keenoy B, et al. Minimally-
invasive and non-invasive continuous glucose monitoring systems: 
Indications, advantages, limitations and clinical aspects. Curr 
Diabetes Rev 2008; 4: 159-68.
28. Joseph JI, Hipszer B, Mraovic B, et al. Clinical need for continuous 
glucose monitoring in the hospital. J Diabetes Sci Technol 2009; 3: 
1309-18.
29. Heinemann L. Glucose Monitoring Study Group. Continuous glucose 
monitoring by means of the micro-dialysis technique: underlying 
fundamental aspects. Diabetes Technol Ther. 2003;5(4):545-61
30. Lorencio C, Leal Y, Bonet A, et al. Real-Time Continuous Glucose 
Monitoring in an Intensive Care Unit: Better Accuracy in Patients 
with Septic Shock. Diabetes Technology & Therapeutics 
2012;4(7):568-75.
31. Holzinger U, Warszawska J, Kitzberger R, et al.  Impact of  shock 
requiring norepinephrine on the accuracy and reliability of 
subcutaneous continuous glucose monitoring. Intensive Care Med 
2009;35:1383–89.
32. Price GC, Stevenson K, Walsh TS. Evaluation of a continuous glucose 
monitor in an unselected general intensive care population. Crit 
Care Resusc 2008;10:209–16.
33. De Block C, Manuel-Y-Keenoy B, Van Gaal L, et al. Intensive insulin 
therapy in the intensive care unit. Diabetes Care 2006;29:1750–56.
34. Pfützner J, Forst T, Butzer R, et al. Performance of the continuous 
glucose monitoring system (CGMs) during the development 
of ketosis in patients on insulin pump therapy. Diabet Med 
2006;23:1124–29.
35. Piper HG, Alexander JL, Shukla A, et al.  Real-time continuous 
glucose monitoring in paediatric patients during and after cardiac 
surgery. Paediatrics 2006;118:1176–84.
36. Goldberg PA, Siegel MD, Russell RR, et al. Experience with the 
Continuous Glucose Monitoring system in a medical intensive care 
unit. Diabetes Technol Ther 2004;6:339–47.
37. Monsod TP, Flanagan DE, Rife F, et al.  Do sensor glucose 
levels accurately predict plasma glucose concentrations 
during hypoglycaemia and hyperinsulinemia? Diabetes Care 
2002;25:889–93.
38. Holzinger U, Warszawska J, Kitzberger R, et al. Real-time continuous 
glucose monitoring in critically ill patients: A prospective 
randomized trial. Diabetes Care. 2010; 33: 467-72.
39. Mraz M, Kopecky P, Blaha J, et al. The use of continuous glucose 
monitoring combined with computer-based eMPC algorithm for 
tight glucose control in cardio-surgical ICU: a feasibility study. Proc 
69th scientific sessions of the American diabetes association, new 
Orleans, la, 2009. 
40. Tonyushkina K, Nichols JH. Glucose meters: a review of technical 
challenges to obtaining accurate results. J diabetes sci Technol 
2009;3:971–80.
41. Rabiee A, Andreasik RN, Abu-Hamdah R, et al. Numerical  and 
clinical accuracy of a continuous glucose monitoring system during 
intravenous insulin therapy in the surgical and burn intensive care 
units. J diabetes sci Technol 2009;3:951–59.  
42. Klonoff DC, Buckingham B, Christiansen JS, et al. Continuous 
Glucose Monitoring: An Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab 2011;96 (10): 2968–79.
43. Ganesh A, Hipszer B, Loomba N, et al. Evaluation of the VIA Blood 
Chemistry Monitor for Glucose in Healthy and Diabetic Volunteers. J 
Diabetes Sci Technol 2008; 2:182-93.
44. Skjaervold NK, Solligard E, Hjelme DR, et al. Continuous 
measurement of blood glucose: Validation of a new intravascular 
sensor. Anaesthesiology 2011; 114:120–25.
